Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody engineered to selectively bind and neutralize interleukin-17A (IL-17A) with a dissociation constant (K_D) of less than 3 pM. This antibody effectively inhibits the interaction of IL-17A with its receptor, IL-17RA, without interacting with other members of the IL-17 cytokine family. Ixekizumab is primarily utilized in research focused on the pathophysiology and treatment of moderate-to-severe plaque psoriasis.
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody engineered to selectively bind and neutralize interleukin-17A (IL-17A) with a dissociation constant (K_D) of less than 3 pM. This antibody effectively inhibits the interaction of IL-17A with its receptor, IL-17RA, without interacting with other members of the IL-17 cytokine family. Ixekizumab is primarily utilized in research focused on the pathophysiology and treatment of moderate-to-severe plaque psoriasis.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
